Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis

Eduardo Mysler, Mariana Caubet, Ana Lizarraga Organización Medica de Investigación, Buenos Aires, ArgentinaCorrespondence: Eduardo Mysler Email e.mysler@omiargentina.com.arAbstract: Rheumatoid arthritis (RA) is the most prevalent form of inflammatory arthritis. It is a profound...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mysler E, Caubet M, Lizarraga A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	rheumatoid arthritis dmards biosimilars. Diseases of the musculoskeletal system RC925-935
Acceso en línea:	https://doaj.org/article/45b1d4dc816145d7b84c99f4c59ddaae
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:45b1d4dc816145d7b84c99f4c59ddaae
record_format	dspace
spelling	oai:doaj.org-article:45b1d4dc816145d7b84c99f4c59ddaae2021-12-02T14:38:25ZCurrent and Emerging DMARDs for the Treatment of Rheumatoid Arthritis1179-156Xhttps://doaj.org/article/45b1d4dc816145d7b84c99f4c59ddaae2021-06-01T00:00:00Zhttps://www.dovepress.com/current-and-emerging-dmards-for-the-treatment-of-rheumatoid-arthritis-peer-reviewed-fulltext-article-OARRRhttps://doaj.org/toc/1179-156XEduardo Mysler, Mariana Caubet, Ana Lizarraga Organización Medica de Investigación, Buenos Aires, ArgentinaCorrespondence: Eduardo Mysler Email e.mysler@omiargentina.com.arAbstract: Rheumatoid arthritis (RA) is the most prevalent form of inflammatory arthritis. It is a profoundly serious and severe disease that if it goes untreated could have severe consequences to the joints and health of the patient who carries this diagnosis. The treatment of RA has dramatically changed since the year 2000, with the discovery of the TNFis, then other biologics, and finally the JAKi. All these new medications with or without methotrexate in combination, tight control and treat to target have produced a revolution in the outcome of this disease. We reviewed and summarized the treatment options, and the most significant papers for each one of these new drugs. The reader could have a full picture with all the references of the recent publications. We also updated the biosimilar situation in RA, as well as the new drugs that will be coming to the market in the next 5 years.Keywords: rheumatoid arthritis, DMARDs, biosimilarsMysler ECaubet MLizarraga ADove Medical Pressarticlerheumatoid arthritisdmardsbiosimilars.Diseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 13, Pp 139-152 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatoid arthritis dmards biosimilars. Diseases of the musculoskeletal system RC925-935
spellingShingle	rheumatoid arthritis dmards biosimilars. Diseases of the musculoskeletal system RC925-935 Mysler E Caubet M Lizarraga A Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
description	Eduardo Mysler, Mariana Caubet, Ana Lizarraga Organización Medica de Investigación, Buenos Aires, ArgentinaCorrespondence: Eduardo Mysler Email e.mysler@omiargentina.com.arAbstract: Rheumatoid arthritis (RA) is the most prevalent form of inflammatory arthritis. It is a profoundly serious and severe disease that if it goes untreated could have severe consequences to the joints and health of the patient who carries this diagnosis. The treatment of RA has dramatically changed since the year 2000, with the discovery of the TNFis, then other biologics, and finally the JAKi. All these new medications with or without methotrexate in combination, tight control and treat to target have produced a revolution in the outcome of this disease. We reviewed and summarized the treatment options, and the most significant papers for each one of these new drugs. The reader could have a full picture with all the references of the recent publications. We also updated the biosimilar situation in RA, as well as the new drugs that will be coming to the market in the next 5 years.Keywords: rheumatoid arthritis, DMARDs, biosimilars
format	article
author	Mysler E Caubet M Lizarraga A
author_facet	Mysler E Caubet M Lizarraga A
author_sort	Mysler E
title	Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
title_short	Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
title_full	Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
title_fullStr	Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
title_full_unstemmed	Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
title_sort	current and emerging dmards for the treatment of rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/45b1d4dc816145d7b84c99f4c59ddaae
work_keys_str_mv	AT myslere currentandemergingdmardsforthetreatmentofrheumatoidarthritis AT caubetm currentandemergingdmardsforthetreatmentofrheumatoidarthritis AT lizarragaa currentandemergingdmardsforthetreatmentofrheumatoidarthritis
_version_	1718390946749480960

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis

Ejemplares similares